drugset / Trial / NCT01043276

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

NCT01043276 ↗

Phase 1 Completed 20 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study if to investiagte the time course of PF-00258210 plasma concentration in the presence or absence of PF-00610335 administered via oral inhalation using dry powder inhalers

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00258210 Unknown 220 ug Inhaled
Subject PF-00258210 Unknown 350 ug Inhaled
Subject PF-00258210 Unknown 440 ug Inhaled
Subject PF-00610335 Unknown 450 ug Inhaled

Indications